Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland · 2026
Detection and treatment of peritoneal metastases in colon cancer: COLOPEC trial compared to routine practice.
СтатьяСравнительное исследованиеМногоцентровое исследованиеРандомизированное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hochstenbach Iris, Hamm Julie J M, Rademaker Eva, Aalbers Arend G J, Boerma Djamila, van Grevenstein Wilhelmina M U, Hemmer Patrick H J, De Hingh Ignace H J T, Kok Niels F M, Tuynman Jurriaan B, Madsen Eva V E, de Wilt Johannes H W, Consten Esther C J, van Westreenen Henderik L, Tanis Pieter J, COLOPEC Collaborators Group, Dutch Snapshot Research Group and Dutch Complex Colon Cancer Initiative
Аннотация
AIM: The randomized COLOPEC trial demonstrated no benefit of adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) in preventing peritoneal metastases in locally advanced colon cancer. Because all patients underwent a diagnostic laparoscopy at 18 months, the study lacked a true control arm, leaving the effect of early detection and treatment compared with standard care uncertain. This study aimed to compare long-term oncological outcomes between patients treated in the COLOPEC trial and patients treated in routine care.
METHOD: Patients who underwent curative resection for c/pT4 or perforated colon cancer in the COLOPEC trial were compared with a retrospective control cohort that included all colon cancer resections performed in 2014-2015, in 50 Dutch hospitals. All 202 trial patients were matched 1:1 to 202 control patients using propensity score matching.
RESULTS: Following treatment in both arms of the COLOPEC trial, compared to the matched control cohort, 5-year overall survival was 70.2% versus 72.8% (p = 0.77). Five-year disease-free survival was 62.1% versus 65.2% (p = 0.31) and five-year cumulative incidence of peritoneal metastases was 24.4% Versus 9.5% (p < 0.001). Cytoreductive surgery with HIPEC for peritoneal recurrence was performed in 28 (13.9%) versus 7 patients (3.5%; p < 0.001).
CONCLUSION: Despite increased detection and more frequent treatment of peritoneal metastases in the COLOPEC trial, 5-year overall and disease-free survival were comparable to routine practice.
METHOD: Patients who underwent curative resection for c/pT4 or perforated colon cancer in the COLOPEC trial were compared with a retrospective control cohort that included all colon cancer resections performed in 2014-2015, in 50 Dutch hospitals. All 202 trial patients were matched 1:1 to 202 control patients using propensity score matching.
RESULTS: Following treatment in both arms of the COLOPEC trial, compared to the matched control cohort, 5-year overall survival was 70.2% versus 72.8% (p = 0.77). Five-year disease-free survival was 62.1% versus 65.2% (p = 0.31) and five-year cumulative incidence of peritoneal metastases was 24.4% Versus 9.5% (p < 0.001). Cytoreductive surgery with HIPEC for peritoneal recurrence was performed in 28 (13.9%) versus 7 patients (3.5%; p < 0.001).
CONCLUSION: Despite increased detection and more frequent treatment of peritoneal metastases in the COLOPEC trial, 5-year overall and disease-free survival were comparable to routine practice.